TRIM39 is a poor prognostic factor for patients with estrogen receptor‐positive breast cancer and promotes cell cycle progression-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

TRIM39 is a poor prognostic factor for patients with estrogen receptor‐positive breast cancer and promotes cell cycle progression

Published:2021-12-08 Issue: Volume: Page:
ISSN:1320-5463
Container-title:Pathology International
language:en
Short-container-title:Pathology International

Author:

Ogura Takuya¹²³,Azuma Kotaro¹,Takeiwa Toshihiko¹,Sato Junichiro⁴,Kinowaki Keiichi⁴^ORCID,Ikeda Kazuhiro⁵,Kawabata Hidetaka²,Inoue Satoshi¹⁵^ORCID

Affiliation:

1. Department of Systems Aging Science and Medicine Tokyo Metropolitan Institute of Gerontology Tokyo Japan

2. Department of Breast and Endocrine Surgery Toranomon Hospital Tokyo Japan

3. Department of Systems BioMedicine Tokyo Medical and Dental University Tokyo Japan

4. Department of Pathology Toranomon Hospital Tokyo Japan

5. Division of Systems Medicine and Gene Therapy Saitama Medical University Saitama Japan

Funder

Japan Society for the Promotion of Science

Yamaguchi Endocrine Research Foundation

Okinaka Memorial Institute for Medical Research

Publisher

Wiley

Subject

General Medicine,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/pin.13190

Reference36 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Incidence Trends of Breast Cancer Molecular Subtypes by Age and Race/Ethnicity in the US From 2010 to 2016

3. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

4. Endocrine resistance in breast cancer – An overview and update

5. TRIM Family Proteins: Roles in Autophagy, Immunity, and Carcinogenesis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research progress of TRIMs protein family in tumors;BIOCELL;2023

2. TRIM family contribute to tumorigenesis, cancer development, and drug resistance;Experimental Hematology & Oncology;2022-10-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3